KZR Kezar Life Sciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KZR

Price (delayed)

$0.8376

Market cap

$60.89M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.22

Enterprise value

$53.94M

Based in South San Francisco, Kezar Life Sciences is combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule ...

Highlights
The debt has grown by 47% YoY but it has contracted by 2.9% from the previous quarter
The quick ratio has shrunk by 55% YoY and by 22% QoQ
The net income has contracted by 37% YoY and by 6% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://kezarlifesciences.com
Peers: OMGA

Key stats

What are the main financial stats of KZR
Market
Shares outstanding
72.69M
Market cap
$60.89M
Enterprise value
$53.94M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.28
Price to sales (P/S)
8.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.71
Earnings
Revenue
$7M
EBIT
-$86.29M
EBITDA
-$85.79M
Free cash flow
-$80.7M
Per share
EPS
-$1.22
Free cash flow per share
-$1.11
Book value per share
$2.97
Revenue per share
$0.1
TBVPS
$3.43
Balance sheet
Total assets
$249.33M
Total liabilities
$33.33M
Debt
$19.56M
Equity
$215.99M
Working capital
$213.84M
Liquidity
Debt to equity
0.09
Current ratio
13.83
Quick ratio
13.51
Net debt/EBITDA
0.08
Margins
EBITDA margin
-1,225.5%
Gross margin
100%
Net margin
-1,254.2%
Operating margin
-1,383.8%
Efficiency
Return on assets
-32%
Return on equity
-36.2%
Return on invested capital
-34.8%
Return on capital employed
-37.1%
Return on sales
-1,232.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KZR stock price

How has the Kezar Life Sciences stock price performed over time
Intraday
0.79%
1 week
-8.16%
1 month
10.36%
1 year
-89.28%
YTD
-88.1%
QTD
-29.61%

Financial performance

How have Kezar Life Sciences's revenue and profit performed over time
Revenue
$7M
Gross profit
$7M
Operating income
-$96.87M
Net income
-$87.79M
Gross margin
100%
Net margin
-1,254.2%
The company's operating income fell by 49% YoY and by 7% QoQ
The net income has contracted by 37% YoY and by 6% from the previous quarter

Growth

What is Kezar Life Sciences's growth rate over time

Valuation

What is Kezar Life Sciences stock price valuation
P/E
N/A
P/B
0.28
P/S
8.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.71
The EPS has declined by 20% year-on-year and by 6% since the previous quarter
The price to book (P/B) is 86% less than the 5-year quarterly average of 2.0 and 72% less than the last 4 quarters average of 1.0
KZR's equity is down by 24% year-on-year and by 7% since the previous quarter

Efficiency

How efficient is Kezar Life Sciences business performance
KZR's ROE is down by 42% YoY and by 14% QoQ
The return on assets has declined by 36% year-on-year and by 11% since the previous quarter
The company's return on invested capital fell by 16% YoY and by 8% QoQ

Dividends

What is KZR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KZR.

Financial health

How did Kezar Life Sciences financials performed over time
KZR's current ratio has dropped by 56% year-on-year and by 22% since the previous quarter
The quick ratio has shrunk by 55% YoY and by 22% QoQ
The debt is 91% less than the equity
KZR's debt to equity has soared by 80% year-on-year
The debt has grown by 47% YoY but it has contracted by 2.9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.